Company news

Skye Bioscience, Inc. news in 2026

Skye Bioscience, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

August 14, 2026

SkyVolt Energy Signs LOI with Modular Data Center Company Nodiac.ai, Unlocking Potential Additional Revenue from strategic Existing and Future Energy Development Assets

June 18, 2026

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

April 6, 2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

April 1, 2026

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 9, 2026

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

March 4, 2026

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

February 2, 2026

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

January 29, 2026

Skye Bioscience to Present Poster at Keystone Obesity Conference

January 21, 2026

Skye Provides 2026 Corporate Outlook

January 12, 2026

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

January 5, 2026

Calls in 2026

Decks in 2026